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Abstract 
A single CpG site within F2RL3 was recently found to be hypomethylated in peripheral blood 
genomic DNA from smokers compared to former and non-smokers. We performed two 
epigenome-wide association studies (EWAS) nested in a prospective healthy cohort using the 
Illumina 450K Methylation Beadchip. The two populations consisted of matched pairs of healthy 
individuals (n=374), of which half went on to develop breast or colon cancer. The association was 
analysed between methylation and smoking status, as well as cancer risk. In addition to the same 
locus in F2RL3, we report several loci that are hypomethylated in smokers compared to former 
and non-smokers, including an intragenic region of the aryl hydrocarbon receptor repressor gene 
(AHRR; cg05575921, p=2.31x10
-15
; effect size = 14%-17%), an intergenic CpG island on 2q37.1 
(cg21566642, p=3.73x10
-13
; effect size = 12%), and a further intergenic region at 6p21.33 
(cg06126421, p=4.96x10
-11
, effect size = 7%-8%). Bisulphite pyrosequencing validated six loci in 
a further independent population of healthy individuals (n=180). Methylation levels in AHRR 
were also significantly decreased (p<0.001) and expression increased (p=0.0047) in the lung 
tissue of current smokers compared to non-smokers. This was further validated in a mouse model 
of smoke exposure. We observed an association with breast cancer risk for the 2q37.1 locus 
(p=0.003, adjusted for smoking status), but not for the other loci associated with smoking. These 
data show that smoking has a direct effect on the epigenome in lung tissue, which is also 
detectable in peripheral blood DNA and may contribute to cancer risk.  
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Introduction 
Epigenetic profiles, including methylation of the 5-carbon of cytosines, are helping to unravel the 
pathogenesis of numerous complex diseases, in particular for diseases that have an environmental 
component to their etiology. Since the first studies by Doll in the 1950s that linked smoking with 
lung cancer risk, smoking has been identified as a major risk factor for numerous cancers. 
However, the molecular changes that occur as a consequence of the neoplastic process itself, in 
addition to changes caused by chemo- and radiotherapy, mean that any investigation into the 
epigenetic alterations induced by cancer risk factors must be performed prospectively in pre-
diagnostic samples.  
Improvements in array-based technology have enabled the molecular effects of altered 
environments, such as cigarette smoke inhalation, to be assessed in larger populations. The only 
study to show a significant link between smoking and the epigenome used the Illumina 27K 
platform and identified a single locus in the F2RL3 gene out of 27,578 loci tested that was less 
methylated in current smokers (n = 65) compared to former (n = 56) and non-smokers (n = 56).(1) 
This gene is associated with platelet activation and coagulation, but cannot be clearly connected to 
the carcinogenic processes that are induced by an individual’s exposure to tobacco smoke.  
The introduction of the Illumina 450K methylation bead array has enabled the analysis of the 
DNA methylation pattern across the genome with additional coverage of promoters, 5’UTRs, first 
exons, gene bodies and 3’UTRs. This study aimed to assess the impact of current and former 
smoking on DNA methylation in an epigenome-wide approach using prospectively collected 
blood samples from healthy individuals who subsequently developed breast or colon cancer 
compared to matched controls. We hypothesised that smoking induces gene specific methylation, 
Page 6 of 32Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Shenker et al.  
4 
 
detectable in peripheral blood DNA and that these exposure induced changes may impact on 
cancer risk. 
 
Results 
Epigenome-wide association studies 
In this study, we performed two epigenome-wide association studies (EWAS) on genomic 
DNA from peripheral white blood cells (WBC) that were prospectively collected from two nested 
case-control studies within a large cohort from the general population. All individuals were 
healthy at the time of blood collection, but cases were selected from individuals who subsequently 
developed either breast or colon cancer (average lag-time to diagnosis = 4.6 and 7 years, 
respectively). These samples were being analysed to identify markers associated with breast 
cancer and colon cancer risk and survival; however, these analyses are under-powered to detect 
genome-wide significant individual markers and will need to be validated in larger sample sizes 
currently underway (see Supplementary Figures 1-2). We have used this data in order to further 
examine the association between methylation in peripheral blood genomic DNA from smokers 
compared to former and non-smokers.(1) For the present analysis, we used multivariate linear 
regression to investigate the association between DNA methylation levels and smoking status, 
adjusting for age and batch. Using a cutoff of p < 1x10
-5
, we identified 17 and 19 loci in the breast 
cancer and colon cancer EWAS, respectively, that were differentially methylated between 
smokers, former smokers and those who had never smoked (Figure 1). Eight of these loci were 
shared by both studies (Table 1). The top hits for both studies (p < 1x10
-5
) are shown in 
Supplemental Table 1. In all instances, the degree of methylation was lower in smokers than non-
smokers, and less difference was found between former smokers and non-smokers. Of note, the 
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F2RL3 locus previously identified was in this list. There was no strong association (p < 1x10
-5
) 
between methylation levels at any of these loci and disease status, despite smoking being a weak 
risk factor for colon cancer (Supplementary Table 2).(2, 3) We observed no evidence for an 
association between smoking and risk of colon cancer in this study (p = 0.857), which was likely 
to be a consequence of the small numbers of participants in the study. One of the smoking-
associated loci (cg01940273) at 2q37.1 showed an association with developing breast cancer, after 
adjustment for smoking (p = 0.003) and estrogen receptor status (p = 0.035). This association 
showed significant heterogeneity by smoking status as it associates with breast cancer case-
control status in a logistic regression model (Interaction P=0.039). This region, therefore, warrants 
further investigation in larger studies as a cancer risk marker and a mechanism for smoking-
induced carcinogenesis.  
 
Bisulphite pyrosequencing validation 
We used bisulphite pyrosequencing on an additional set of healthy subjects (n = 180) to 
validate the methylation association with smoking using an alternative method. We validated the 
methylation of six CpG sites identified by the 450K array (2 CpG sites in AHRR, 2 CpG sites in 
2q37, 1 CpG site in F2RL3 and 1 CpG site in 6p21.33). The direction of methylation change and 
effect sizes were of the same magnitude in the validation groups, and again, a significant 
association with smoking was observed (Table 1). There was also remarkable evidence for an 
association between methylation levels and smoking intensity for the AHRR, 2q37 and 6p21 loci 
(p < 6.09e-05), but not F2RL3, with individuals smoking ≥4 cigarettes per day having 
significantly lower methylation levels at these genomic loci (Supplementary Figure 4, 
Supplementary Table 3). In former smokers, methylation levels at these genomic loci returned to 
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the levels of non-smokers with increasing time from cessation and those who had smoked more 
intensively had methylation levels that were closer to that of current smokers (Supplementary 
Figure 5).  
Regional association plots showing the intragenic CpG island in AHRR and the intergenic CpG 
island at 2q37 are shown in Figure 2 with examples and pyrosequencing validation shown in 
Supplementary Figure 6. The CpG site in one of the AHRR regions of interest (AHRR_p1, 
cg23576855) was also the site of a CGCA SNP (rs6869832), with an A allele frequency of 
approximately 10% as confirmed by pyrosequencing (Figure 3). Minor allele (A) carriers (n = 31) 
were excluded from the pyrosequencing statistical analysis, as the cytosine could not be 
methylated in the CpA dinucleotide. Interestingly, three of the current smokers in the validation 
set were heterozygous carriers; their methylation levels (mean, 37.7%) were approximately half of 
the value found in smokers who were homozygous for the G allele (mean, 66.9%; Table 1). This 
indicated that the CpG site on the G allele was methylated to a similar degree as homozygous G 
alleles. We did not have genotyping data on the individuals in the EWAS sample sets, but predict 
that the individuals with ~40% and 5% β-values are likely to be heterozygous and homozygous 
for this SNP, respectively (Supplementary Figure 6).  
 
Methylation and expression in human and mouse lung tissue 
Pyrosequencing assays were conducted on bisulphite-converted genomic DNA extracted from 
27 human lung samples. We have investigated lung tissue in this case to assess the most relevant 
tissue to the initial exposure. A marked association was present between smoking status and 
methylation levels in human lung tissue. As in peripheral circulating mononuclear cell DNA, 
methylation levels at cg23576855 and cg21161138 in the AHRR gene were significantly decreased in 
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current smokers (p = 0.00327 and 0.00143, respectively) (Figure 4A). The methylation values in 
lung tissue were also identical to those shown in PBMCs, which suggests that blood sampling 
could offer a useful surrogate for future biomarker studies of lung tissue methylation for this gene. 
Expression analyses using qRT-PCR for AHRR in human lung samples from smokers vs. 
non-smokers (n = 5 for each group) was inversely correlated with methylation levels (R
2
=0.157) 
and showed increased expression by 5.7-fold (p = 0.0047) in the current smokers compared to the 
non-smokers (Figure 4B). In a mouse model of smoke exposure (4), smoking significantly 
increased the levels of Ahr and Cyp1a1 in a time-dependent manner compared to controls (Figure 
4C), while Ahrr expression was initially reduced 2.6-fold after the initial exposure to smoke (3 d; 
p = 4.56x10
-6
), but increased by 1.7-fold after 28 d (p = 0.003). Methylation of the Ahrr locus was 
not performed as this intragenic CpG island region is not conserved in the mouse genome. 
 
Discussion 
The findings from these three groups of individuals give strong evidence for the role of 
smoking in inducing changes in DNA methylation levels. In this study, we have validated 
previously identified associations with methylation and smoking for the F2RL3 and AHRR probes 
and have identified further AHRR probes that were significantly associated with smoking.(1, 5) 
We have identified these in two cancer case-control studies using the Illumina 450K methylation 
beadchip and validated them by bisulphite pyrosequencing in an additional validation cohort. Our 
study has identified two novel loci, at 2q37.1 and 6p21, which are also strongly associated with 
smoking status. Importantly, we show for the first time that one of these loci, 2q37.1, is also 
associated with breast cancer risk. Lastly, we show that these associations between smoking and 
methylation are unlikely to be cell type specific differences due to different blood cell proportions.  
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Previous evidence has suggested that intragenic methylation levels are correlated with 
expression levels, with highly expressed genes having high levels of intragenic methylation, and 
vice versa.(6-8) According to this rationale, we predicted that decreased levels of methylation in 
the AHRR gene in smokers would indicate lower levels of expression. In the smoke-exposed mice, 
this was indeed the case with short-term exposure (3 d), but the consequent increase in Ahrr 
expression after 28 d of smoke exposure suggest that other compensatory mechanisms of gene 
induction override the short-term decrease in expression marked by lower intragenic DNA 
methylation levels. This supports data that shows an increase in Ahrr expression following 
exposure to benzo(a)pyrene, a chemical found in cigarette smoke, in a mouse model.(9) In 
humans, the expression of AHRR in lung tissue mirrored the long term exposure in mice, however, 
the observed hypomethylation of this locus in lung tissue may be an indicator of past expression 
changes in this differentiated tissue type. 
A recent study of 165 individuals on the 450K methylation array identified a single CpG site 
within the AHRR gene associated with smoking status in EBV-transformed lymphoblastoid cell 
lines.(5) With a larger study size of 554 individuals, we have validated the association and 
identified additional intragenic CpG sites in the AHRR gene associated with smoking in white 
blood cell DNA and lung tissue. The aryl hydrocarbon receptor (AHR) is a crucial receptor in the 
pathway that metabolizes a range of biological compounds and synthetic environmental 
pollutants. Benzopyrene and dioxin-like compounds are highly toxic organic molecules that are 
released from various components of cigarettes during smoking and enter the circulation via the 
pulmonary vasculature. These compounds are metabolised by AhR,(10, 11) releasing further 
carcinogenic metabolites that have been implicated in lung cancer development.(12). However, 
the AHR pathway may also mediate carcinogenesis through other pathways such as oxidative 
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stress.(13) AHRR (aryl hydrocarbon receptor repressor; chromosome position 5p15.33) encodes 
for a class E basic helix-loop-helix protein,(14) which is mainly found in the cytoplasm. It inhibits 
the translocation of the AHR-ligand complex into the nucleus by disrupting the binding of AHR to 
the AHR-nuclear translocator (AHRNT).(15) The AHR-AHRNT heterodimer also inhibits the 
transcription of AHRR in a feedback loop. The knockdown of AHRR has been shown to produce 
increased tumour cell invasiveness in a range of tissue types, including breast, colon, lung, and 
ovarian. (16, 17) An increase of the repressor of the AHR pathway should lead to a decrease in the 
activity of the pathway, and therefore, a decrease in AHR pathway-mediated carcinogenesis. 
However, the data from our study shows an increase in AHRR expression and decreased intragenic 
methylation due to smoking, with no evidence of an association with breast or colon cancer risk. 
Therefore, more work is needed to understand the complex mechanisms of smoking induced 
carcinogenesis via the AHR pathway.  
A novel finding of this study was that a genomic locus, comprising four consecutive probes at 
2q37.1, was differentially methylated between smokers and former or non-smokers. The four 
probes are located within 824 bp of an intergenic CpG island (chr2: 233,284,112 – 233,284,935; 
http://genome.ucsc.edu/, hg19). This region maps to a DNase hypersensitivity site within a CpG 
island, indicating a possible regulatory region (Supplemental Figure 7),(18) and is a potential 
pseudogene of ECEL1 (endothelin-converting enzyme-like 1; chr2: 233,344,537 to 233,351,464 
bp, 60,425 bp downstream of 2q37), as it possesses a high level of sequence homology (>95%). 
We observed an association with breast cancer risk at this locus with significant heterogeneity in 
the effect in smokers compared to non-smokers. While the estimate of breast cancer risk 
associated with smoking is still unclear (19), future work on larger case control studies will be 
needed to validate this cancer association. We hypothesize that molecular markers of smoking 
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exposure, such as methylation markers described here, will provide more accurate measurement 
of the exposure than questionnaire based data and allow a more robust assessment of any 
associated cancer risk. Whether this 2q37 locus is causally linked to breast cancer risk due to 
smoking is not yet known, however, if verified we hypothesize that the mechanism may involve in 
cis regulation of the developmentally regulated homologue, ECEL1. There are several limitations 
in establishing causality between an epigenetic trait, an exposure and cancer risk. These include 
the reversible nature of epigenetic modifications and the need for an appropriate tissue type in 
which to investigate gene expression – methylation associations (for example a large 
epidemiology sized sample set of normal breast tissue prior to disease onset). 
A second novel intergenic locus with lower methylation levels in smokers was at 6p21.33 (chr 
6: 307,020,080). This locus is in a gene desert which maps onto a DNase I hypersensitivity site 
and transcription factor binding site, associated with an H3K27 acetylated chromatin site, which is 
often associated with active regulatory elements. It is not associated with any gene or SNP. 
Further studies will be required to assess the functional nature of these two novel intergenic 
genomic loci.  
Toxic components of cigarette smoke enter the bloodstream via the alveolar capillary system, 
after which they could directly affect the epigenetic profile of circulating WBC. For the loci that 
correlated with smoking status, we showed a strong correlation with time since quitting and 
duration of smoking, with methylation levels eventually returning to those of non-smoker levels. 
This is an observation that has been seen for methylation at the F2RL3 locus using the 27K 
methylation chip,(20) and in the gene expression signature of smoking for some genes.(21) 
Interestingly, the expression of some genes, including AHRR, do not return to previous levels, 
which indicates a long-term gene expression consequence of prior smoking history that may be 
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locked in by DNA methylation changes.(21) However, we have to consider the possibility that 
other confounding factors may influence this association. We and others have not adjusted for 
alcohol and body mass index, which may be smoking-associated or methylation-associated 
confounding factors. Furthermore, we have assessed methylation levels in the genomic DNA of 
all circulating WBC. Smoking increases the circulating WBC count;(22) although the effect of 
cigarette smoke on specific WBC types have not been assessed in large-scale populations, it may 
be that subsets with different methylation levels are clonally expanded due to the exposure, which 
might affect the overall methylation result. Using fractionation of blood cell types into T-cells, B-
cells, monocytes, granulocytes and buffy coat (all leukocytes) compared to whole blood cell DNA 
from the same individuals we have shown no evidence that any of these blood cell types have 
significantly different methylation levels that would confound the association with smoking 
(Supplementary Table 6). Lastly, genetic haplotype differences between individuals tagging allele 
specific methylation may confound associations with smoking status if such haplotypes are also 
associated with smoking (23). We have performed a preliminary analysis of 25 individuals for 
which we have both GWAS data and EWAS 450K methylation data (unpublished data). We 
found evidence for potential allele specific methylation at the F2RL3 locus (general logistic 
regression p=0.01), but not for the other smoking associated loci (Supplementary Table 7). While 
the AHRR CG>CA SNP (cg23576855, presented in Figure 3) does indeed influence the 
methylation of this site and is in linkage disequilibrium with the haplotype tag SNP, it does not 
influence allele specific methylation of the haplotype given that the two other nearby CpG sites 
(79bp and 26,061 bp apart from the first site) show no evidence of allele specific methylation 
(p=0.798; p=0.916, respectively). Therefore, for the majority of loci it is unlikely that the 
methylation association with smoking reported in this study is due to genetic polymorphism. 
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Taken together, these studies report a strong link between tobacco use and a direct biological 
result on the epigenome, which is detectable in blood and lung tissue, and may impact on the 
cancer risk associated with smoking. The level of methylation was directly associated with 
smoking intensity and duration, however, the biological consequences of these epigenetic 
alterations will require further investigation, particularly at these novel intergenic loci. The results 
of our study and others regarding a key gene in the AHR pathway may have relevance beyond 
tobacco smoke exposure given the key role played by this pathway in the metabolism of many 
environmental carcinogens. 
 
Materials and Methods 
Subject recruitment 
Study participants were drawn from the Italian component of the European Prospective 
Investigation into Cancer and Nutrition cohort, a large general population cohort consisting of 
~520,000 individuals with standardised lifestyle and personal history questionnaires, 
anthropometric data and blood samples collected for DNA extraction.(24, 25) In this study, we 
used the Torino sub-cohort (EPIC-Turin) which consists of ~10,000 subjects. For the microarray 
component of this study we included 92 incident female breast cancer cases and 92 matched 
controls and 95 incident colon cancer cases and 95 matched controls including 68 male and 27 
female pairs. Controls were individually matched on age (±5 years), sex, seasonality of blood 
collection and duration of follow-up. Blood samples from cancer cases were taken 55 months 
before diagnosis on average (range, 24-108 months) for breast cancer cases and 84 months before 
diagnosis (range, 0.2-173 months) for colon cancer cases (Supplementary Table 5). Blood cell 
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type fractionation was performed on six healthy volunteers using magnetic bead separation 
(EasySep, StemCell Technologies, France).  
 
Microarray protocol 
For the microarray, DNA samples were extracted using the QIAsymphony DNA Midi Kit 
(Qiagen, Crawley, UK). Bisulphite conversion of 500 ng of each sample was performed using the 
EZ-96 DNA Methylation-Gold™ Kit (Zymo Research, Orange, CA). Bisulphite-converted DNA 
was used for hybridisation on the Infinium HumanMethylation 450 BeadChip, following the 
Illumina Infinium HD Methylation protocol. The methylation score for each CpG was represented 
as a β-value according to the fluorescent intensity ratio representing any value between 0 
(unmethylated) and 1 (completely methylated). Raw microarray data and processed normalised 
data will be available from Gene Expression Omnibus (GEO) (accession TBA).  
 
Validation of array-based methylation results by pyrosequencing 
For the validation component of this study, 180 healthy control individuals were randomly 
sampled from females enrolled in the EPIC-Turin cohort. This group comprised 33 current 
smokers, 45 former smokers and 102 individuals who had never smoked. Genomic DNA (250 ng) 
from each subject was bisulphite converted as above. For pyrosequencing, specific primers were 
designed for six CpG loci using PyroMark software (Qiagen, Hilden Germany), and PCR 
conditions were as described previously.(26) (Supplemental Table 6). Methylation values were 
calculated as an average of all high quality CpG sites, which were determined as “passed” by the 
quality control thresholds within the Pyro Q-CpG software (Qiagen). Pyrosequencing assays for 
three loci (cg05951221, cg01940273 and cg05575921) could not be designed. 
Page 16 of 32Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Shenker et al.  
14 
 
 
Human and murine expression analyses 
Human lung samples (n=27, 14 smokers, 13 non-smokers) were obtained from either lung 
transplants performed at The Royal Brompton or Harefield Hospital or purchased from IIAM 
(International Institute for the Advancement of Medicine, Edison, NJ). In all cases, the tissue was 
consented for use in scientific research and ethics approval obtained from the Royal Brompton & 
Harefield Trust. DNA was extraction and pyrosequencing was performed as described above. 
RNA was extracted from lung tissue (n=5 smokers, n=5 non-smokers), and quantitative RT-PCR 
(qRT-PCR) was performed on a Bio-Rad PCR machine with SyBR green (Sigma), for AHRR 
normalised against GAPDH, using standard protocols. Lung tissue was collected from ten mice 
exposed to air (n=5) or cigarette smoke (n=5), as described previously.(7) RNA was extracted and 
qRT-PCR was performed for Ahrr, Ahr, Cyp1a1 and F2rl3 as described above, using a ribosomal 
gene, Rpl7, as the internal reference standard. 
 
Statistical analysis 
For the statistical analysis, raw data was exported from GenomeStudio (Illumina) as background 
subtracted β-values with corresponding detection p-values. Following quality control the resulting 
data sets included 86 breast cancer cases with 87 matched controls (86 matched pairs) and 95 
colon cancer cases and 95 matched controls. Overall, 484,804 probes were analysed in the breast 
cancer data set and 485,152 in the colon cancer data set. There were no significant genome-wide 
methylation differences between smokers, former and never smokers in raw β-values 
(Supplementary Figure 6); therefore, the data was normalised using quantile normalisation. 
Multivariate linear regression was used to identify associations between methylation β-values as 
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the outcome and coded smoking status as the exposure (0, 1 and 2 for ‘Never’, ‘Former’ and 
‘Current’ smokers, respectively), adjusting for age and batch. A secondary analysis was 
performed that also adjusted for case-control status, which did not significantly alter the results 
(Supplementary Table 2). P-values less than 1x10
-7
 were considered to be significant at the level 
of epigenome-wide significance. We found no evidence for a bias towards probes containing 
SNPs or type I or type II probes in probes associated with smoking. For association with smoking 
intensity, coded intensity categories were used as the exposure, Time to quitting and duration of 
smoking in former smokers were analysed as continuous variables. Attributable risk for the 2q37 
locus was calculated as the difference in rate of hypomethylation between an exposed population 
(cancer cases) and an unexposed population (healthy controls), stratified by smoking status. All 
analyses were performed in R, v2.13.1. Gene expression levels were compared between the 
control and smoke-exposed human or mouse lung tissue using Student’s t-tests with P <0.05 
considered significant. 
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Figure Legends 
Figure 1: Manhattan plot and quantile-quantile plot for EWAS results for smoking status in 
two case-control studies.  
A) Breast cancer case-control study. B) Colon cancer case-control study. In the Manhattan plot, 
the vertical axis indicates (-log10 transformed) observed p-values, and the horizontal thresholds 
indicate the significance levels of p = 1 x 10
−5
 and p = 1 x 10
-7
. In the quantile-quantile (QQ) plot, 
the horizontal axis shows (-log10 transformed) expected p-values, and the vertical axis indicates (-
log10 transformed) observed p-values. The lambda inflation factor (median[obs]/median[exp]) is 
shown. 
 
Figure 2: Regional association plots showing two regions associated with smoking status 
AHRR (A) and 2q37.1 intergenic CpG island (B). Regional association plots are shown with 
the gene map (from UCSC genome browser, hg19) with a graph of -log10 p-values on the y-axis 
and nucleotide position on the x-axis for the breast cancer EWAS (blue diamonds), colon cancer 
EWAS (red circles) and pyrosequencing validation (black asterisks).  
 
Figure 3: Pyrosequencing validation of AHRR locus cg23576855 reveals a CG>CA single 
nucleotide polymorphism (rs6869832). Boxplots represent pyrosquencing-based methylation 
levels of individuals with the homozygous G allele in the validation control population. 
Heterozygotes and homozygotes for the minor A allele are marked as a cross and show the same 
relationship to smoking status.  
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Figure 4: Smoking induces methylation and expression changes in human and mouse lung 
tissue. A) Pyrosequencing data from two regions of interest, presented as boxplots, in human lung 
tissue samples from smokers (n=14) vs. never smokers (n=13). For cg23576855 individuals 
heterozygous for the CG>CA polymorphism are marked as crosses. B) AHRR mRNA expression 
data from human lung tissue from smokers (n=5) versus non-smokers (n=5), showing a 5.7-fold 
increase in expression in smokers compared to non-smokers (upper panel) and correlation 
between methylation and expression in the same 5 non-smokers (grey circles) and 5 smokers 
(black triangles) (lower panel). C) Mouse lung expression changes in AHRR and F2RL3, in 
addition to two other genes from the aryl hydrocarbon receptor pathway, AHR and CYP1A1. As 
predicted, AHR and CYP1A1 increase in response to cigarette smoke, and the expression of 
AHRR initially decreases after 3 days, before increasing after 28 days. There was no significant 
change in the expression of F2RL3 after exposure to cigarette smoke. 
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Table 1: Leading differentially methylated genomic loci between smokers and former or non-smokers in a breast and colonic 
case-control cohort. This list contains the top eight overlapping CG sites between the breast cancer and colon cancer EWAS studies, 
in addition to an additional site within the 2q37.1 locus that was also validated by pyrosequencing. Rows in bold indicate the data that 
was independently validated by bisulphite pyrosequencing of that locus in a separate EPIC cohort of healthy individuals (n = 180) 
with known smoking status. 
Chr, chromosome; FDR, false discovery rate; nd, not done; n/a, not applicable. 
 
 
* Logistic regression adjusting for age and batch effect; ** effect size represents percentage methylation difference between current smokers 
and individuals who have never smoked. Pyrosequencing assays could not be designed for three of the nine CpG sites. 
 
 
 
 
Target ID Chr MAPINFO (bp) Symbol 
Β-values in breast cancer case-control 
cohort 
Β-values in colon cancer case-control cohort Pyrosequencing methylation in the 
validation cohort 
Never Former Current 
P-value * 
Effect 
size 
(%) 
** Never Former Current 
P-value * 
Effect 
size 
(%) 
** Never Former Current 
P-value  
(FDR) 
 
Effect 
size  
(%)  
** 
cg06644428 2 233284112 2q37.1 0.07 0.05 0.05 6.17E-07 2 0.11 0.09 0.09 3.38E-04 3 12.11 11.02 8.11 1.48E-05 4 
cg05951221 2 233284402 2q37.1 0.39 0.33 0.28 1.80E-13 11 0.41 0.37 0.34 1.83E-07 7      
cg21566642 2 233284661 2q37.1 0.44 0.37 0.32 3.73E-13 12 0.51 0.47 0.39 4.41E-08 12 58.86 53.04 40.11 2.22E-08 18.75 
cg01940273 2 233284934 2q37.1 0.58 0.56 0.49 1.47E-10 9 0.62 0.59 0.54 5.96E-09 8      
cg23576855 5 373299 AHRR 0.66 0.64 0.5 3.46E-06 16 0.73 0.68 0.53 9.66E-06 20 82.68 80.17 66.91 1.51E-12 15.77 
cg05575921 5 373378 AHRR 0.84 0.79 0.68 2.31E-15 17 0.84 0.81 0.7 1.73E-09 14      
cg21161138 5 399360 AHRR 0.66 0.65 0.6 5.44E-08 5 0.72 0.71 0.68 8.29E-06 4 75.47 74.67 68.3 3.22E-05 7.17 
cg03636183 19 17000585 F2RL3 0.64 0.61 0.56 8.38E-11 8 0.68 0.65 0.61 3.84E-07 7 62.19 60.92 54.32 0.00172 7.87 
cg06126421 6 30720080 6p21.33 0.65 0.61 0.57 4.96E-11 8 0.71 0.7 0.64 2.46E-06 7 67.4 66.8 59.5 0.00095 7.88 
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Abbreviations 
AHR, aryl hydrocarbon receptor 
AHRR, aryl hydrocarbon receptor repressor 
CpG, cytosine-guanine dinucleotide 
EWAS, epigenome-wide association study 
F2RL3, coagulation factor II (thrombin) receptor-like 3 
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